Bonus BioGroup Ltd. (BBIXF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 44.88 Million ILS | -39.84% |
| 2022 | 74.61 Million ILS | -28.48% |
| 2021 | 104.32 Million ILS | 102.82% |
| 2020 | 51.43 Million ILS | 635.87% |
| 2019 | 6.99 Million ILS | -31.19% |
| 2018 | 10.15 Million ILS | 82.14% |
| 2017 | 5.57 Million ILS | 92.58% |
| 2016 | 2.89 Million ILS | -49.69% |
| 2015 | 5.75 Million ILS | 27.26% |
| 2014 | 4.52 Million ILS | -44.55% |
| 2013 | 8.15 Million ILS | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 32.01 Million ILS | -17.59% |
| 2024 Q1 | 38.85 Million ILS | -13.45% |
| 2023 Q4 | 44.88 Million ILS | -14.0% |
| 2023 Q2 | 59 Million ILS | -11.32% |
| 2023 Q3 | 52.19 Million ILS | -11.54% |
| 2023 FY | 44.88 Million ILS | -39.84% |
| 2023 Q1 | 66.53 Million ILS | -10.82% |
| 2022 Q1 | 105.75 Million ILS | 1.38% |
| 2022 FY | 74.61 Million ILS | -28.48% |
| 2022 Q4 | 74.61 Million ILS | -8.01% |
| 2022 Q3 | 81.11 Million ILS | -16.84% |
| 2022 Q2 | 97.53 Million ILS | -7.78% |
| 2021 Q3 | 117.11 Million ILS | 21.28% |
| 2021 FY | 104.32 Million ILS | 102.82% |
| 2021 Q2 | 96.56 Million ILS | -18.38% |
| 2021 Q1 | 118.3 Million ILS | 130.01% |
| 2021 Q4 | 104.32 Million ILS | -10.92% |
| 2020 Q4 | 51.43 Million ILS | 33.74% |
| 2020 FY | 51.43 Million ILS | 635.87% |
| 2020 Q3 | 38.46 Million ILS | -1.17% |
| 2020 Q2 | 38.91 Million ILS | -9.87% |
| 2020 Q1 | 43.17 Million ILS | 517.68% |
| 2019 Q4 | 6.99 Million ILS | -31.42% |
| 2019 Q2 | 8.81 Million ILS | -24.76% |
| 2019 Q1 | 11.71 Million ILS | 15.36% |
| 2019 FY | 6.99 Million ILS | -31.19% |
| 2019 Q3 | 10.19 Million ILS | 15.59% |
| 2018 Q2 | 8.76 Million ILS | 62.25% |
| 2018 FY | 10.15 Million ILS | 82.14% |
| 2018 Q4 | 10.15 Million ILS | -9.8% |
| 2018 Q1 | 5.4 Million ILS | -3.14% |
| 2018 Q3 | 11.26 Million ILS | 28.49% |
| 2017 Q1 | 4.09 Million ILS | 41.3% |
| 2017 Q3 | 4.47 Million ILS | -12.89% |
| 2017 Q4 | 5.57 Million ILS | 24.63% |
| 2017 FY | 5.57 Million ILS | 92.58% |
| 2017 Q2 | 5.13 Million ILS | 25.54% |
| 2016 Q2 | 3.93 Million ILS | -31.87% |
| 2016 Q1 | 5.77 Million ILS | 0.4% |
| 2016 FY | 2.89 Million ILS | -49.69% |
| 2016 Q4 | 2.89 Million ILS | -43.54% |
| 2016 Q3 | 5.12 Million ILS | 30.28% |
| 2015 Q2 | 5.11 Million ILS | 39.25% |
| 2015 Q1 | 3.67 Million ILS | -18.84% |
| 2015 FY | 5.75 Million ILS | 27.26% |
| 2015 Q4 | 5.75 Million ILS | 63.71% |
| 2015 Q3 | 3.51 Million ILS | -31.22% |
| 2014 Q4 | 4.52 Million ILS | 26.02% |
| 2014 Q2 | 5.09 Million ILS | -28.42% |
| 2014 Q1 | 7.12 Million ILS | -12.69% |
| 2014 FY | 4.52 Million ILS | -44.55% |
| 2014 Q3 | 3.58 Million ILS | -29.6% |
| 2013 Q3 | 8.14 Million ILS | 40.27% |
| 2013 FY | 8.15 Million ILS | 0.0% |
| 2013 Q2 | 5.8 Million ILS | -19.53% |
| 2013 Q4 | 8.15 Million ILS | 0.16% |
| 2013 Q1 | 7.21 Million ILS | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ContraFect Corporation | 20.67 Million USD | -117.075% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Ember Therapeutics, Inc. | 184.00 USD | -24396095.652% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -1534.506% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -8895.089% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -15.553% |
| Kadimastem Ltd | 2.3 Million USD | -1848.24% |
| Zenith Capital Corp. | 7410.00 USD | -605689.474% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -31297.057% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -49.555% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -58690.633% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -11645.605% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 65.526% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -61931.369% |
| Qrons Inc. | 420.00 USD | -10687757.143% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -196945.784% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -13849.087% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -4677.006% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -10297.856% |
| Affymax, Inc. | 7.44 Million USD | -503.104% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 89.942% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -2192.373% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -982.7% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -1943146.753% |
| Biomind Labs Inc. | 73.81 Thousand USD | -60709.548% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 14.823% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -17080.617% |
| CytoDyn Inc. | 11.13 Million USD | -303.098% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -325.327% |
| IMV Inc. | 31.33 Million USD | -43.261% |
| Genus plc | 1.02 Billion USD | 95.637% |
| Halberd Corporation | 10.13 Thousand USD | -442985.579% |
| Helix BioMedix, Inc. | 3.02 Million USD | -1383.892% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -521.752% |
| LadRx Corporation | 2.3 Million USD | -1845.03% |
| Marizyme, Inc. | 22.01 Million USD | -103.901% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -250957.047% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -27.602% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -11399.208% |
| Q BioMed Inc. | 3.51 Million USD | -1176.882% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -12594.243% |
| Enzolytics Inc. | 361.7 Million USD | 87.59% |
| CSL Limited | 38.02 Billion USD | 99.882% |
| Skye Bioscience, Inc. | 11.94 Million USD | -275.942% |
| SQZ Biotechnologies Company | 107.18 Million USD | 58.121% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -1254.93% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -3204.664% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -17074.898% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -6917.678% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 5.897% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -7059.33% |
| NovAccess Global Inc. | 62.24 Thousand USD | -72013.16% |
| HST Global, Inc. | 1526.00 USD | -2941512.058% |
| SYBLEU INC | 330.46 Thousand USD | -13483.463% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 65.07% |
| Alpha Cognition Inc. | 2.45 Million USD | -1730.583% |
| AVAX Technologies, Inc. | 7.37 Million USD | -508.486% |
| Mesoblast Limited | 667.9 Million USD | 93.279% |
| MultiCell Technologies, Inc. | 126.22 USD | -35563994.438% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -3034.637% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -6429.442% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -5724.869% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 90.302% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -1624.38% |
| GB Sciences, Inc. | 103.44 Thousand USD | -43295.333% |
| argenx SE | 4.54 Billion USD | 99.012% |
| Resverlogix Corp. | 8.11 Million USD | -453.161% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -2290.408% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -60.639% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -2998.265% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -401.6% |
| ONE Bio Corp. | 70.08 Million USD | 35.951% |
| Genscript Biotech Corporation | 3.38 Billion USD | 98.674% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -4737.38% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -4443.573% |
| Agentix Corp. | 261.39 Thousand USD | -17073.058% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | -208.297% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -78522.973% |
| Cell Source, Inc. | 195.17 Thousand USD | -22899.831% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -9241.036% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -12594.243% |
| Itoco Inc. | 1.4 Million USD | -3106.192% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -46827.041% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -42248.113% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -11545.234% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -8030.298% |
| Rebus Holdings, Inc. | 5000.00 USD | -897680.0% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -10863.993% |
| Mobile Lads Corp. | 52.00 USD | -86324900.0% |
| International Stem Cell Corporation | 5.39 Million USD | -732.82% |
| Bioxytran, Inc. | 137.63 Thousand USD | -32513.813% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -199.223% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -170.758% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -56721.519% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -5091.418% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -497.166% |
| Neutra Corp. | 2851.00 USD | -1574400.175% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -38.521% |
| PureTech Health plc | 693.97 Million USD | 93.532% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -456.17% |
| IXICO plc | 15.84 Million USD | -183.32% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -442.007% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 56.555% |
| CSL Limited | 38.02 Billion USD | 99.882% |
| Cellectis S.A. | 333.99 Million USD | 86.56% |